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Hydroxylation is an emerging modification generally catalyzed by a family of 70 enzymes that are depen-
dent on oxygen, Fe(II), ascorbate, and the Kreb’s cycle intermediate 2-oxoglutarate (2OG). These ‘‘2OG oxy-
genases’’ sit at the intersection of nutrient availability and metabolism where they have the potential to
regulate gene expression and growth in response to changes in co-factor abundance. Characterized 2OG
oxygenases regulate fundamental cellular processes by catalyzing the hydroxylation or demethylation (via
hydroxylation) of DNA, RNA, or protein. As such they have been implicated in various syndromes and dis-
eases, but particularly cancer. In this review we discuss the emerging role of 2OG oxygenases in gene
expression control, examine the regulation of these unique enzymes by nutrient availability andmetabolic in-
termediates, and describe these properties in relation to the expanding role of these enzymes in cancer.Congratulations! Today is your day. You’re off to Great
Places! You’re off and away!—Dr. Seuss (Oh, The Places
You’ll Go!)Introduction
Hydroxylation was first identified as a post-translational modifi-
cation following fundamental biochemical experiments per-
formed in the mid-20th century investigating the source of
hydroxy-proline and -lysine in collagen. The demonstration
that these were not derived from their correspondingly modified
free forms paved the way for partial purification of the first pro-
tein hydroxylases in the 1960s (Kivirikko and Prockop, 1967).
Even at this embryonic stage, it was appreciated that the inhibi-
tion of hydroxylase activity due to nutrient deprivation could
result in disease (i.e., scurvy). The fact that abnormal collagen
hydroxylase activity was the basis of Ehlers-Danlos syndrome
also highlighted that hydroxylase mutations can cause disease
(Hyland et al., 1992). What was not appreciated was that
the collagen hydroxylases belonged to a wider family of oxy-
genases and that, collectively, these enzymes are involved in
a variety of fundamental biological processes and diseases,
particularly cancer.
The potential importance of hydroxylation in cancer was first
discussed in the 1990s following the discovery of asparaginyl
and aspartyl hydroxylation in extracellular EGF repeats (Stenflo
et al., 1989). Deletion of the b-aspartyl/asparaginyl hydroxylase
(BAH) gene in mice promotes colorectal cancer in an APC/min
model (Dinchuk et al., 2002), while an association between its
overexpression in tumors and poor prognosis may relate to roles
in motility, invasion, proliferation, and survival (Dong et al., 2015).
The potential pro-tumorigenic properties of BAH have led re-
searchers to consider it as a biomarker and therapeutic target
in several cancers.
The new millennium heralded a surge in hydroxylation re-
search, following the seminal discovery that oxygen-dependentmodification of a hypoxia-inducible transcription factor (HIF)
was the basis for oxygen sensing and hypoxic adaptation (dis-
cussed in detail below). The discovery that hydroxylation of a
transcription factor could link nutrient availability to a physiolog-
ical response also signaled a new paradigm in gene expression
control. It has since become apparent that control of gene
expression is a theme that unifies many members of this
enzyme family. In this review, we describe the role of hydroxyl-
ation at each step of gene expression. We will discuss the
unique position of this oxygenase family at the intersection of
nutrient availability and metabolism and consider that this un-
derlies a general role in gene expression control and cancer.
We begin by providing a brief introduction to the biochemistry
of this family of oxygenases (for comprehensive reviews, see
Hausinger, 2004; Loenarz and Schofield, 2008; McDonough
et al., 2010).
2-Oxoglutarate Oxygenases
Hydroxylases generally belong to a family of70 oxygenase en-
zymes in mammals whose activities depend on key nutrients,
including oxygen, Fe(II), the Kreb’s cycle intermediate 2-oxoglu-
tarate (2OG), and in some cases a reducing agent such as
ascorbate (Loenarz and Schofield, 2011). The family can be
subdivided into groups based on sequence and structural ho-
mology and/or function (Figure 1). 2OG oxygenases are ancient
enzymes present in the earliest forms of life, where they catalyze
a variety of different oxidative modifications (Hausinger, 2004).
Although the only reaction described in higher organisms thus
far is hydroxylation, a large subset of 2OG oxygenases utilize
this activity to catalyze demethylation (Figure 2A) (Klose et al.,
2006). Despite this more restricted biochemistry, biological di-
versity is driven by their ability to target all the major biological
macromolecules, including DNA, RNA, protein, and lipid (Loe-
narz and Schofield, 2008). In the context of protein, those eu-
karyotic 2OG oxygenases characterized thus far catalyze the
hydroxylation of prolyl, lysyl, asparaginyl, aspartyl, and histidyl
residues (see below). Additional activities in prokaryotes (e.g.,Molecular Cell 58, June 4, 2015 ª2015 Elsevier Inc. 729
Figure 1. Functional Clustering of
2-Oxoglutarate Oxygenases
(A) 2OG oxygenases that target proteins. 2OG
oxygenases catalyze hydroxylation (lower right)
and demethylation (upper left) (via a hydroxylation
reaction). Upper left: The JmjC histone demethy-
lases (KDMs) are one of the largest groups of
2OG oxygenases. These can be divided into sub-
groups (colored circles/ovals) that share sequence
homology and common histone targets (also see
Figure 3A). Note that some KDMs also have non-
histone substrates (e.g., KDM7C/4C). ALKBH4 is
an actin lysyl demethylase. Lower right: 2OG
oxygenases catalyzing stable protein hydroxyl-
ation are a major functional family. These can also
be divided into sub-groups (colored circles/ovals,
see key), where clustering represents a common
biological target (e.g., collagen, yellow circle) or
physiological process (e.g., translation, red oval).
Enzyme names are written in light italic font if the
corresponding substrate is uncertain or unknown.
(B) 2OG oxygenases that target nucleic acids.
TYW5 and ALKBH8 catalyze hydroxylation of
specific tRNAs (red circle). TET enzymes (blue
oval) hydroxylate methylated DNA at 5-mC.
ALKBH5 and FTO demethylate m6A in mRNA.
ALKBH2/ALKBH3 demethylate DNA damaged by
alkylation (purple circle). Also see Figure 3B. JmjC-
only 2OG oxygenases are marked with an asterix.
Not all members of the 2OG oxygenase family are
represented here (lipid oxygenases have been
omitted, for example).
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laxed substrate specificities of some 2OG oxygenases (Yang
et al., 2013a), suggest that hydroxylation of other amino acids
may yet be described in eukaryotes. Despite the biochemical
diversity of the 2OG oxygenase family, individual enzymes
generally catalyze highly context-dependent modifications,
with specificity driven by the primary sequence of the substrate
and structural motifs within the enzyme (McDonough et al.,
2010).
The 2OG oxygenase catalytic domain is characterized by a
double-stranded b helix (DSBH) fold comprised of eight antipar-
allel b strands that fold into a barrel-like structure with an opening
at one end (Figure 2B). This arrangement brings together key
amino acid side chains involved in binding the co-factors (Fe(II)
and O2), co-substrate (2OG), and the prime substrate (McDo-
nough et al., 2010). Whereas Fe(II) is coordinated by a conserved
‘‘2-His/1-carboxylate’’ motif (HxD/E . H) (Figure 2C), residues
involved in 2OG binding are more variable, but consistent within
sub-families. The catalytic cycle is initiated by 2OG binding,
which facilitates substrate and subsequent oxygen binding.
Oxidative decarboxylation of 2OG generates a highly reactive in-
termediate that mediates oxidation of the prime substrate, with
the production of CO2 and succinate as byproducts (Figure 2D).730 Molecular Cell 58, June 4, 2015 ª2015 Elsevier Inc.Gene Expression Control: Modify
DNA, RNA, and Protein
Pathways that signal to gene expression
and growth control are tightly regulated
by mitogens, nutrient availability, and
metabolism and are frequently the target
of genetic and epigenetic alterations incancer (Hanahan and Weinberg, 2011). Accumulating evidence
indicates that 2OG oxygenases often act in these pathways
and are commonly altered in tumors. Before discussing how
this emerging theme may relate to their position at the interface
of nutrient availability andmetabolism, we will first describe 2OG
oxygenases that target each step in gene expression (from DNA
to RNA to protein) and summarize evidence supporting a role for
these enzymes in cancer.
DNA Hydroxylation and Demethylation
Ten-Eleven Translocation
DNA methylation is a critical regulator of gene expression that is
commonly altered in cancer. Methyltransferases generally target
the carbon-5 position of cytosine in CpG dinucleotides to create
5-methylcytosine (5-mC), a dynamic epigenetic modification
that canbe actively andpassively reversed. Active reversal is initi-
ated by the ‘‘Ten-Eleven Translocation’’ (TET) sub-family of 2OG
oxygenases (TET1–TET3) (Figures 2Aand3B), sonamedbecause
the TET1 gene on chromosome 10 is the target of a translocation
with the mixed-lineage leukemia (MLL) gene (chromosome 11) in
myeloid and lymphoidmalignancies (HuangandRao, 2014). TETs
hydroxylate the methyl group of 5-mC to form 5-hydroxymethyl-
cytosine (5-hmC), followed by additional subsequent oxidations.
Figure 2. Enzymology of 2-Oxoglutarate Oxygenases: Overview of Reactions, Catalytic Cycle, and Structural Features
(A) Oxidative modifications catalyzed by eukaryotic 2OG oxygenases. Upper panel: Stable hydroxylation of protein and tRNA. Middle panel: Hydroxylation of
methyl-cytosine in DNA by TET enzymes (subsequent arrows denote additional oxidations in a demethylation process, see text). Lower panel: demethylation of
histones andmethyl-adenosine (m6A) in mRNA. Hydroxylation creates an unstable intermediate that decomposes into the unmethylated form plus formaldehyde
(CHOH).
(B) Topology of the 2OG oxygenase catalytic domain. The double-stranded b helix (DSBH, green) forms a barrel-like shape that positions essential residues that
ligate co-factors and the prime substrate.
(C) Co-factor binding residues within the DSBH. Magnification of (B) showing Fe(II) (black sphere), Fe(II)-binding residues (orange), 2OG (green), and 2OG-binding
residues (blue).
(D) Simplified graphical representation of the catalytic cycle. Hydroxylation is initiated by 2OG binding, followed by the substrate and subsequently oxygen
(1). One atom of oxygen is incorporated into the prime substrate and the other into CO2 with succinate as a byproduct (2). Hence, these enzymes are classed as
‘‘dioxygenases’’. Some 2OG oxygenases require ascorbate for full activity. Structural images in (B) and (C) are derived from PDB: 3OUJ using Chimera.
Molecular Cell
ReviewThese products facilitate demethylation in multiple ways, in-
cluding an active excision and repair pathway (Kroeze et al.,
2015). Although often considered an intermediate in demethyla-
tion, evidence also supports a direct signaling role for 5-hmC,
which can accumulate to substantial levels and is capable of
binding ‘‘reader’’ proteins (Mellén et al., 2012).
TET1 is relatively infrequently altered in cancer compared to
TET2. Whole-exome sequencing has identified a large number
of TET2 cancer mutations, the majority of which cluster in the
DSBH domain and impair activity. As such, TET2 is one of the
most frequently mutated genes in acute myeloid leukemia,
chronic myelomonocytic leukemia, and myelodysplastic syn-
dromes (Ko et al., 2015). However, the role of TETs and 5-hmC
in gene expression control and cancer likely extends beyond he-
matological malignancies. TET mutations have been described
in a variety of solid cancers (Huang and Rao, 2014). Furthermore,
global 5-hmC levels are commonly reduced in tumors, often inthe absence of TETmutations, likely due to reduced TET expres-
sion and/or activity (Kroeze et al., 2015). Interestingly, TET activ-
ity is altered by co-factor availability and ‘‘oncometabolites’’ in
specific tumor contexts (see below).
ALKB Homologs
In addition to enzymatic methylation, DNA is also subject to
methylation damage by endogenous and exogenous agents.
Alkylated DNA is repaired in E.coli by three repair proteins, one
of which (AlkB) is a 2OG oxygenase (Falnes et al., 2007). AlkB
repairs N1-methyladenosine (1-meA) and N3-methylcytosine
(3-meC) by hydroxylation of the methyl group, which, unlike
5-hmC, is highly unstable, rapidly decomposing into the unme-
thylated and repaired base (with formaldehyde as a byproduct)
(Figures 2A and 3B). There are eight human homologs of E.coli
AlkB (ALKBH1–ALKBH8), and their functions extend beyond
DNA repair (see below). Although ALKBH1 sharesmost similarity
to AlkB and was originally reported to demethylate 3-meC inMolecular Cell 58, June 4, 2015 ª2015 Elsevier Inc. 731
Figure 3. 2-Oxoglutarate Oxygenases
Target the Gene Expression Pathway
(A) JmjC histone demethylases. KDM families
target the indicated methylated lysyl residues of
histones H3 and H4. Histone H2A may support
ALKBH1 activity, although a modification has not
been proven (designated by ‘‘?’’).
(B) Oxidation of DNA modifications by 2OG oxy-
genases. TET enzymes hydroxylate 5-methyl-
cytosine (5-mC) in CpG islands. ALKBH2/ALKBH3
demethylate alkylated cytosine (3-methylcytosine,
3-meC) and adenosine (1-methyladenosine, 1-
meA).
(C) Hydroxylases control a hypoxia signaling
pathway. Prolyl hydroxylases (PHD1–PHD3)modify
hypoxia-inducible transcription factor (HIFa) to
signal itsproteasomaldegradation.Factor inhibiting
HIF (FIH) hydroxylates and inactivates a trans-
activation domain. In hypoxia, inhibition of PHDs
and FIH stabilizes HIFa, which binds with HIFb
to hypoxia response elements (HREs) to activate
transcription of target genes such as vascular
endothelial growth factor (VEGF).
(D) 2OG oxygenases in mRNA biology. ALKBH5/
FTO demethylates methyl-adenosine (6-meA).
Jmjd6 hydroxylates specific lysyl residues in
U2AF65.
(E) Translational hydroxylases. ALKBH8 and
TYW5 hydroxylate hypermodified nucleotides in
the indicated tRNAs (mcm5U = 5-methoxy-
carbonylmethyluridine). NO66, MINA53, and
OGFOD1 target specific residues of the indicated
ribosomal proteins. The colored spheres in the
large 60S and small 40S ribosomal subunits indi-
cate the relative position of the hydroxylated res-
idue, not the position of the protein within the
ribosomal structure (H39/H216 of Rpl27a/Rpl8 are
in disordered loops that extend into the core).
Jmjd4 hydroxylates the stop codon-decoding
domain of eRF1, the eukaryotic release factor.
eRF1 and the GTPase eRF3A mediate stop
codon recognition and peptidyl-tRNA hydrolysis.
m7G = 7-methylguanosine cap.
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gest a role in binding and/or modifying histone H2A (Korvald
et al., 2011; Lando et al., 2012; Ougland et al., 2012). Rather,
ALKBH2 and ALKBH3 have the clearest functional homology
to AlkB (Aas et al., 2003). Interestingly, the DNA repair activity
of ALKBH2 plays a role in gene expression control, enabling
the high transcription rate from ribosomal DNA (rDNA) genes
by promoting their repair (Li et al., 2013). It will be interesting to
determine whether ALKBH2/3 also promotes the expression of
other highly transcribed genes in a similar fashion. Furthermore,
DNA repair is likely the mechanism by which ALKBH2/3 sup-
presses cancer arising from chemically induced colitis (Calvo
et al., 2012). Conversely, some tumor cells are dependent on
overexpression of ALKBH3 to suppress DNA damage and drive
tumorigenesis (Dango et al., 2011). Other ALKBH family mem-
bers have functions that are distinct from ALKBH2/3. Those tar-
geting RNA will be discussed in the relevant sections that follow.
Histone Demethylation
A major level of gene expression control takes place at the
N-terminal tails of histones, where a large variety of post-732 Molecular Cell 58, June 4, 2015 ª2015 Elsevier Inc.translational modifications occur, including methylation. These
dynamic modifications influence chromatin structure and the
recruitment of ‘‘readers’’ that regulate transcription. Interest in
histone methylation has exploded following the discovery of a
sub-family of 2OG oxygenases that catalyzes its reversal (Klose
et al., 2006). This family of 20 enzymes (Figure 1) shares a
specific form of the DSBH catalytic fold known as the Jumonji
C (JmjC) domain. Of the 2OG oxygenases reviewed here, the
family of JmjC histone lysyl demethylases represents the largest
and most well characterized with respect to gene expression
control and cancer.
JmjC histone demethylases that target each of the common
lysyl methylation sites have been identified (Figure 3A). Similar
to the hydroxylation of N-methyl marks in DNA by ALKBH2/3,
hydroxylation of the methylated ε-amino group in histone lysines
is unstable and rapidly decomposes to release formaldehyde
and the unmethylated lysyl residue (Figure 2A). JmjC lysine de-
methylases (KDMs) can be grouped into sub-families (KDM2–
KDM7) that share sequence homology within the DSBH, similar
substrate specificity, and common domain architecture (Figures
1A and 3A).
Molecular Cell
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transcriptional initiation and elongation. However, rather than
acting as powerful transcriptional switches, these enzymes
generally act as modifiers. For example, genome-wide chro-
matin immunoprecipitation and expression studies indicate
that although KDMs often bind to a large population of genes,
they only regulate the transcription of a subset (Kooistra and
Helin, 2012). It is thought that the non-regulated genes maintain
KDM occupancy to prevent inappropriate histone methylation.
However, this combination of housekeeping and regulatory roles
means that KDMs have been widely implicated in fundamental
processes, and consequently in many diseases (Johansson
et al., 2014). Whereas specific KDMs may be associated with a
single disease, the whole family has been implicated in a variety
of cancer ‘‘hallmarks’’ (Højfeldt et al., 2013). In fact, KDMs were
implicated in cancer prior to their JmjC domain being assigned
as having demethylation activity. For example, the GASC1
(KDM4C) gene lies in an amplicon at 9p23-24 that had been
observed in a variety of tumor types. The histone demethylase
activity of KDM4C was subsequently implicated in suppressing
heterochromatin formation and promoting tumor growth (Cloos
et al., 2006). The KDM4 sub-family comprises four other mem-
bers that have also been widely implicated in cancer and
comprehensively reviewed elsewhere (Berry and Janknecht,
2013). The H3K27 demethylase KDM6A (UTX) is probably the
most frequently mutated KDM across human cancers. Although
it displays many of the hallmarks of a tumor suppressor (re-
viewed in Van der Meulen et al., 2014), mutation can correlate
with improved survival in some cases (Kandoth et al., 2013).
To further highlight the role of KDMs in gene expression
control and cancer, we will focus on the KDM5 family, which
has been widely implicated in tumorigenesis. We direct the
reader to other recent reviews for detailed information on the re-
maining KDM sub-families and cancer (Berry and Janknecht,
2013; Højfeldt et al., 2013; Johansson et al., 2014; Van der Meu-
len et al., 2014).
KDM5
The KDM5 family consists of four members (KDM5A–KDM5D)
that demethylate histone H3 Lys-4 (H3K4) (Figure 3A). KDM5A
was recently highlighted as one of 127 significantly mutated
genes in over 3,000 tumors from multiple cancer types (Kandoth
et al., 2013). KDM5A was originally implicated in the regulation
of differentiation and transcription by the Retinoblastoma (Rb)
tumor suppressor protein (Benevolenskaya et al., 2005).
Consistent with KDM5A being an important target of Rb, loss
of KDM5A decreases tumorigenesis in Rb heterozygous
knockout mice (Lin et al., 2011). KDM5A is overexpressed in
several cancers where it promotes multiple cancer-associated
processes (Blair et al., 2011). The deleterious role of KDM5A
in cancer appears multi-faceted: a sub-population of highly dy-
namic tumor cells are rendered ‘‘drug-tolerant’’ by KDM5A
overexpression (Sharma et al., 2010). Interestingly, KDM5B
may also play a role in tumor heterogeneity. It is required in a
sub-population of very slow-cycling melanoma cells to evade
drug treatment and support tumor growth (Roesch et al.,
2010). KDM5B also promotes breast cancer proliferation by re-
pressing expression of the BRCA1 tumor suppressor (Yamane
et al., 2007). Consistent with an important role in this tumortype, KDM5B is commonly amplified in luminal breast cancers,
where it is represses a luminal-specific expression program to
maintain proliferation (Yamamoto et al., 2014). In contrast to
its homologs, KDMC may be tumor suppressive rather than
oncogenic. Next-generation sequencing has identified inacti-
vating KDM5C mutations in clear cell renal cell carcinoma
(Dalgliesh et al., 2010).
JmjC-Only 2OG Oxygenases
JmjC KDM enzymes share several features in common that
allow them to be considered as an independent group within
the 2OG oxygenase family. These include the presence of a
variety of functional motifs that mediate protein:protein inter-
actions, DNA-binding, and targeting to specific histone tail
modifications (Klose et al., 2006). They also share similarities
in sequence and structure within the JmjC domain, which
underpins their common function (McDonough et al., 2010).
Importantly, however, the JmjC domain is not limited to this
sub-family of 2OG oxygenases and is not restricted to catalyzing
lysine demethylation. A phylogenetically discrete group of 2OG
oxygenases also contains JmjC catalytic domains, but in the
absence of other functional motifs (at least based on primary
sequence analyses) (Johansson et al., 2014; Klose et al.,
2006). Some of these ‘‘JmjC-only’’ 2OG oxygenases have
been reported to have KDM activity.
Jmjd5 is a JmjC-only 2OG oxygenase that was originally char-
acterized in breast cancer cells, where it was suggested to
promote proliferation via H3K36me2 demethylation and tran-
scriptional activation of the cyclin A1 locus (Hsia et al., 2010).
A role for Jmjd5 in regulating chromosomal segregation was
also proposed to involve de-repression of Jmjd5 H3K36me2 de-
methylation activity by RCCD1 (Marcon et al., 2014). However,
structural studies indicated that the JmjC domain of Jmjd5 is un-
likely to accommodate a methylated lysyl residue, consistent
with its limited homology to that of the JmjC KDM family (Del
Rizzo et al., 2012; Wang et al., 2013).
Two other members of the JmjC-only family, MINA53 and
NO66, have been reported to possess KDM activity. MINA53
was originally described as a nucleolar-localized Myc target
gene whose expression is commonly deregulated in cancer
(Eilbracht et al., 2005; Tsuneoka et al., 2002). Subsequently,
MINA53 was reported to catalyze H3K9me3 demethylation
and to regulate the transcription of rDNA (Lu et al., 2009).
NO66 shares significant sequence and structural homology to
MINA53 and has also been implicated in cancer and transcrip-
tional regulation (Eilbracht et al., 2004; Sinha et al., 2010; Suzuki
et al., 2007). Despite this homology, NO66 was assigned a
distinct and unusual H3K4/K36 demethylase activity (Sinha
et al., 2010). Similar to Jmjd5, recent structural analyses suggest
that the catalytic pocket within the JmjC domain of MINA53
and NO66 is unlikely to accommodate a methylated lysine
(Chowdhury et al., 2014), which may be consistent with
biochemical analyses showing a lack of demethylase activity
in vitro (Williams et al., 2014). Unbiased proteomic screens
recently led to the discovery that MINA53 and NO66 are histidyl
hydroxylases with substrates in protein translation (see below)
(Ge et al., 2012; Williams et al., 2014). Therefore, the targets of
these enzymes involved in transcriptional regulation may require
further investigation.Molecular Cell 58, June 4, 2015 ª2015 Elsevier Inc. 733
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hydroxylases (Chowdhury et al., 2014), it is possible that they
share some targets in common. This would raise the possibility
of chromatin hydroxylation by JmjC-only enzymes, which could
partly explain some confusion in the assignment of JmjC activ-
ities. For example, Jmjd6 was described as a histone argininyl
demethylase (Chang et al., 2007) before proteomic screens iden-
tified it as a lysyl hydroxylase of splicing factors (see below)
(Webby et al., 2009). Perhaps consistent with similarities in the
primary sequence of these splicing factors and histones,
Jmjd6 has also been reported to catalyze low-level histone hy-
droxylation (Unoki et al., 2013).
Regulation of Transcription Factor Activity
By far the most famous example of gene expression control
by hydroxylation, with wide-reaching implications for tumor
biology, is that of HIF. HIF is a heterodimeric bHLH transcription
factor complex consisting of a dynamically regulated a subunit
(of which three isoforms exist, 1a, 2a, and 3a) and a constitutively
expressed b subunit (Ratcliffe, 2013). HIFa is expressed at very
low levels in well-oxygenated cells due to proteasomal targeting
by three prolyl hydroxylases (PHD1–PHD3/EGLN1–EGLN3).
PHD2 (EGLN1) is considered to be the dominant HIF hydroxylase
in most tissues, whereas PHD3 (EGLN3) is induced by HIF as
part of a negative feedback loop in vivo (Jaakkola and Rantanen,
2013). Hydroxylation by PHDs creates a recognition motif for the
pVHL E3 ubiquitin ligase subunit, a tumor suppressor gene
frequently deleted in renal cell carcinoma (Shen and Kaelin,
2013). Reduced PHD activity in hypoxia blocks HIFa degradation
(the oxygen dependence and sensing role of these enzymes will
be discussed below), resulting in dramatic induction of HIFa pro-
tein, which becomes fully activated following inhibition of a fourth
hydroxylase called factor inhibiting HIF (FIH) (Figure 3C). FIH
suppresses HIF activity in normoxia by hydroxylating an aspara-
ginyl residue in a critical HIFa transactivation domain, which ab-
lates its binding to the transcriptional co-activator p300/CBP
(Lisy and Peet, 2008).
HIF activation initiates a transcriptional program that regulates
hundreds of genes. ChIP-seq analysis has identified more
than 500 binding sites for HIF in the human genome (Schödel
et al., 2013), both at promoters and more distal regions,
which can also be functionally relevant. For example, a SNP
associated with susceptibility to renal cell carcinoma located in
a distal enhancer of the cyclin D1 gene allows HIF2a to bind
and drive overexpression in VHL-deficient RCC (Schödel et al.,
2012). HIF target genes also regulate cell survival, invasion,
angiogenesis, metabolism, differentiation, and epigenetics (Rat-
cliffe, 2013; Shen and Kaelin, 2013). Although this program has
evolved to allow survival and adaption in response to physiolog-
ical hypoxia, the same programs are hijacked in hypoxic and
‘‘pseudo-hypoxic’’ tumor cells. As such, the HIF pathway is
widely implicated in malignancy (Ratcliffe, 2013; Semenza,
2010; Shen and Kaelin, 2013).
Of the three HIF prolyl hydroxylases, PHD2 and PHD3 have
been most widely implicated in cancer. PHD2 may have
opposing effects on tumorigenesis through tumor cell-intrinsic
functions and effects on the microenvironment. Partial loss of
endothelial PHD2 reduces metastasis by normalizing tumor734 Molecular Cell 58, June 4, 2015 ª2015 Elsevier Inc.vasculature via HIF-induced VEGF receptor (Mazzone et al.,
2009), whereas tumor cell PHD2 is reported to inhibit growth
and angiogenesis in xenograft assays (Bordoli et al., 2011; Su
et al., 2012). Consistent with a tumor-suppressive role of PHD2
in some contexts, germline mutations have been reported in
paraganglioma patients, with loss of heterozygosity in the tumor
(Ladroue et al., 2008; Yang et al., 2015). However, such muta-
tions are considered rare (Astuti et al., 2011).
Several lines of evidence also implicate PHD3 activity in tumor
suppression. PHD3 promotes neuronal apoptosis in response to
limited nerve growth factor (NGF) signaling during development
(Schlisio, 2009). Mutations in NF1, c-RET, SDH, or VHL are
thought to repress PHD3 expression or function, leading to
reduced neuronal apoptosis and pheochromocytoma. Consis-
tent with this, loss of PHD3 increases the number of neurons in
the superior cervical ganglion (Bishop et al., 2008). Furthermore,
activation of PHD3 induces apoptosis and tumor suppression in
an A375 melanoma cell xenograft model (Tennant and Gottlieb,
2010). The role of PHD3 in apoptosis is dependent on specific
HIF isoforms in some contexts but is HIF independent in others.
Therefore, other pathways may play a role downstream of PHD3
in specific biological contexts. In relation to this, other substrates
of the HIF PHDs have been proposed that may be unrelated to
HIF biology (reviewed in Wong et al., 2013; Zheng et al., 2014).
Although further characterization of these substrates may be
required, it is of interest that they include proteins involved in
gene expression control, metabolism, and cancer (Wong et al.,
2013; Zheng et al., 2014).
Regulation of RNA Biology
In addition to a major role in transcriptional regulation through
modification of DNA and histones, 2OG oxygenases also control
gene expression at the level of RNA. Here they have been shown
to directly target mRNA and tRNA and to regulate mRNA
splicing.
Splicing
Jmjd6 proteomic screens identified a variety of associated
proteins involved in RNA metabolism, particularly arginine-
serine (RS)-rich domain proteins (Webby et al., 2009). Consis-
tent with this, Jmjd6 regulates splicing of reporter genes and
endogenous mRNAs (Boeckel et al., 2011; Webby et al.,
2009) (Figure 3D). Although these effects may be independent
of enzyme activity (Heim et al., 2014), Jmjd6 does catalyze
low-level lysyl hydroxylation of the U2AF65 splicing factor
(Webby et al., 2009). Interestingly, it has been proposed
that, through its effects on splicing, Jmjd6 promotes angio-
genesis by suppressing expression of the soluble form of
the VEGF receptor Flt-1 (Boeckel et al., 2011). Consistent
with multiple roles in cancer, Jmjd6 also regulates growth,
migration, and invasion and is associated with poor prognosis
in lung and breast cancer (Lee et al., 2012). Whether these
attributes reflect Jmjd6’s role in splicing control is not yet
known.
N6-Methyladenosine Demethylases
Methylation of adenosine to N6-methyladenosine (6-meA) is a
common nucleotide modification present in approximately
25% of mRNAs and is generally located in the 50 UTR or in
the proximity of the stop codon (reviewed in Meyer and
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ReviewJaffrey, 2014). 6-meA has been implicated in mRNA splicing,
translation, and stability. Similar to methylated DNA and his-
tones, 6-meA is a dynamic modification. It is deposited by a spe-
cific methyltransferase complex and reversed by at least two
2OG oxygenases, FTO and ALKBH5 (Figure 3B).
ALKBH5 is a nuclear enzyme of the ALKBH family. Interest-
ingly, ALKBH5 is a HIF target gene (Thalhammer et al., 2011),
which may place its expression under the indirect control of
the HIF hydroxylases. Similar to the mechanism of histone
lysine demethylation, hydroxylation of 6-meA by ALKBH5 or
FTO creates an unstable intermediate, which decomposes
into adenosine plus formaldehyde (Meyer and Jaffrey, 2014)
(Figure 2A). Unlike ALKBH5, FTO is significantly expressed in
the cytoplasm. Therefore, it has been proposed that ALKBH5
and FTO are unlikely to be functionally redundant. Interest-
ingly, sequence variants within introns 1 and 8 of the FTO
gene are associated with increased risk of breast cancer
and melanoma, respectively (Garcia-Closas et al., 2013; Iles
et al., 2013).
tRNA Hydroxylases
In addition to mRNA, RNA modifications are also found in other
RNA classes, including tRNA. A variety of modifications have
been described in the anticodon stem and loop region of tRNAs
and are proposed to regulate translational fidelity and tRNA
folding (El Yacoubi et al., 2012). For example, phenylalanine
tRNA contains a hypermodified base, hydroxywybutosine,
which is synthesized in a biosynthetic pathway involving the
hydroxylase TYW5 (Figure 3E) (Noma et al., 2010). Similarly,
5-methoxycarbonylmethyluridine (mcm5U) is a hypermodified
base within the anticodon loop of Arg- and Gly-tRNA, which
is hydroxylated by a member of the ALKBH family, ALKBH8
(van den Born et al., 2011) (Figure 3E). ALKBH8 knockdown
suppresses tumor xenograft growth due to cell cycle arrest,
increased apoptosis, and reduced angiogenesis and invasion
(Shimada et al., 2009).
Translational Hydroxylases
Protein synthesis is becoming increasingly recognized as an
important level of gene expression control that is heavily regu-
lated by growth factor signaling and nutrient-sensing pathways.
Unsurprisingly, therefore, the loss of translational control is often
described in disease (Le Quesne et al., 2010). Indeed, enhanced
ribosome biogenesis and deregulated protein synthesis are
considered hallmarks of cancer (Silvera et al., 2010). If 2OG oxy-
genases are key mediators of gene expression control and
tumorigenesis, then one might predict that protein synthesis is
an important target. The role of ALKBH8 and TYW5 in tRNA hy-
permodification, together with that of ALKBH2 in maintaining
rDNA transcription, would be consistent with this possibility. In
this section we review recent reports that have identified addi-
tional hydroxylase targets in protein synthesis.
Ribosomal Oxygenases
Three 2OG oxygenases have recently been identified as ribo-
somal protein hydroxylases. OGFOD1 is a prolyl hydroxylase
of the small subunit protein Rps23, where it modifies Pro-62, a
highly conserved residue located within the decoding center of
the ribosome (Katz et al., 2014; Loenarz et al., 2014; Singleton
et al., 2011) (Figure 3E). Perhaps consistent with a fundamentalrole in translation, loss of OGFOD1 activity caused altered trans-
lational accuracy and reduced protein synthesis associated with
increased autophagy and reduced growth.
The two remaining ribosomal oxygenases identified thus far
are MINA53 and NO66, which were introduced earlier in relation
to reported KDM activities and roles in transcription. These 2OG
oxygenaseswere recently shown to be histidyl hydroxylases that
target large ribosomal subunit proteins: MINA53 hydroxylates
His-39 of Rpl27a, while NO66 modifies His-216 of Rpl8 (Ge
et al., 2012) (Figure 3E). In both cases the modified residue is
located within a disordered loop that extends deep into the ribo-
some. Interestingly, the modification site in Rpl8 is close to the
peptidyl-transferase center. Although the function of these mod-
ifications in translation is not yet clear, MINA53 and NO66 have
been implicated in a variety of malignant phenotypes (Komiya
et al., 2010; Suzuki et al., 2007; Tsuneoka et al., 2002). Further
work is required to determine the relative contribution of tran-
scriptional versus translational control to the role of these en-
zymes in tumorigenesis.
Translation Factor Hydroxylation
Like MINA53 and NO66, Jmjd4 is a JmjC-only 2OG oxygenase.
Although Jmjd4 is most closely related to the carbon-5 lysyl hy-
droxylase Jmjd6, it does not interact with the RS domain-splicing
factors mentioned earlier. Rather, proteomic analyses identified
Jmjd4 as a carbon-4 lysyl hydroxylase that targets eRF1 (Feng
et al., 2014) (Figure 3E), the eukaryotic translational termination
factor. Jmjd4 hydroxylates Lys-63 within the stop codon-decod-
ing domain of eRF1, a residue previously implicated in contact-
ing the invariant uridine in stop codons. Indeed, Jmjd4 activity
and eRF1 Lys-63 hydroxylation are required for optimal transla-
tion termination in vivo and in vitro (Feng et al., 2014). Interest-
ingly, copy number variations in the Jmjd4 gene indicate it is
amplified in a variety of tumor types, most frequently in breast
and liver carcinomas (14% and 11%, respectively) (http://
www.cbioportal.org). This may be consistent with the fact that
genes regulating translation are commonly overexpressed in
rapidly proliferating tumor cells in order to sustain elevated pro-
tein synthesis and cell growth (Silvera et al., 2010).
2-Oxoglutarate Oxygenases Act at the Interface of
Nutrient Availability and Metabolism
Together, the research described above supports gene expres-
sion control as a major function of 2OG oxygenases. There they
act at the very foundations of the genetic code through to the
final stages of protein synthesis. It is perhaps unsurprising that
2OG oxygenases are so heavily implicated in tumorigenesis,
considering the central role of gene expression in cell growth
and division and the deregulation of these processes in cancer.
The basis for gene expression control by 2OG oxygenases may
relate to their unique position at the interface of nutrient availabil-
ity and metabolism (Figure 4). The activity of 2OG oxygenases
depends on fundamental nutrients and an essential Kreb’s cycle
intermediate. Has evolution harnessed the chemistry of 2OG
oxygenases to link the availability of these nutrients and metab-
olites to control of gene expression, growth, and homeostasis?
To explore this further, we discuss the evidence supporting a
role for 2OG oxygenases as nutrient-responsive enzymes.
Although the majority of work in this area currently relates toMolecular Cell 58, June 4, 2015 ª2015 Elsevier Inc. 735
Figure 4. 2-Oxoglutarate Oxygenases as Sensors of Nutrient
Availability and Metabolism in Gene Expression Control and Cancer
Nutrient availability: The availability of fundamental nutrients (ascorbate, Fe(II),
and oxygen) and an important Kreb’s cycle intermediate (2OG) can determine
the activity of some 2OG oxygenases and, in turn, their ability to regulate gene
expression and cancer-associated process. Fe(II) loading of some 2OG oxy-
genases by chaperones of the PCBP family regulates their activity. Meta-
bolism: Elevated levels of D-2-hydroxyglutarate (D-2HG), succinate, and
fumarate result from mutations in isocitrate dehydrogenase (IDH), succinate
dehydrogenase (SDH), and fumarate dehydrogenase (FH), respectively. High
levels of these ‘‘oncometabolites’’ (indicated by colored arrows) compete with
2OG and inhibit oxygenase activity in cancer. The Kreb’s cycle is depicted by
gray arrows.
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other 2OG oxygenases regulated by co-factor availability.
Oxygen
A paradigm for nutrient-sensing by 2OG oxygenases is provided
by the HIF hydroxylases. PHD activity is reduced under con-
ditions of limited oxygen, which prevents proteasomal degrada-
tion of HIFa. The affinity of PHDs for oxygen may not be
dissimilar to some other hydroxylases, however, suggesting
that other factors also likely contribute to the potential of a
2OG oxygenase to act as an oxygen sensor (Ratcliffe, 2013).
Interestingly, the activity of FIH toward HIF is less sensitive to
hypoxia than the PHDs in some contexts (Lisy and Peet, 2008).
This difference may allow the HIF pathway to fine-tune the
magnitude and repertoire of target gene activation in response
to a range of oxygen tensions.
Outside of the HIF system, there has been comparatively lit-
tle analysis of potential oxygen sensing by other 2OG oxy-
genases, except for some preliminary analyses on the KDM
family. Increased histone methylation during hypoxia is thought
to be due to a combination of an increase in the activity of spe-
cific methyltransferases toward some sites and the inhibition of
JmjC KDMs that target others (reviewed in Melvin and Rocha,
2012). Indeed, proof-of-principle experiments indicate that
KDM4E activity is regulated by oxygen in a physiologically rele-
vant range in vitro and that KDM4E reacts with oxygen slowly,
similar to PHD2 (Sánchez-Fernández et al., 2013). Furthermore,
a global induction of H3K4me3 in hypoxia may be due to inhi-
bition of KDM5A (Zhou et al., 2010). Interestingly, a role for
KDMs in the hypoxia response is supported by their general736 Molecular Cell 58, June 4, 2015 ª2015 Elsevier Inc.transcriptional regulation by HIF (reviewed in Shmakova et al.,
2014).
The activity of recently characterized protein hydroxylases
(Jmjd4, MINA53/NO66, OGFOD1) has also been tested in hyp-
oxia. However, even in severe hypoxia (0.1%), these transla-
tional hydroxylases retain significant activity, similar to FIH
(Feng et al., 2014; Ge et al., 2012; Singleton et al., 2014). This
may highlight the likelihood that not all 2OG oxygenases will
act in oxygen-sensitive signaling modules. However, the poten-
tial for ‘‘range-finding’’ raises the possibility that a 2OG oxy-
genase could be more oxygen sensitive in a specific context
(Ratcliffe, 2013). For example, it is interesting to note that eRF1
hydroxylation is more sensitive to hypoxia in cells that express
lower levels of Jmjd4 (Feng et al., 2014). Furthermore, the
expression of translational hydroxylases may be modestly sup-
pressed by hypoxia (Pollard et al., 2008).
Fe(II)
2OG oxygenases may have the potential to sense Fe(II) availabil-
ity, since binding of Fe(II) to the active site of these enzymes is
relatively labile. Indeed, early studies on HIF hydroxylases illus-
trated that supplementation of tissue culture media with Fe(II)
was sufficient to promote hydroxylase activity (Knowles et al.,
2003). More recently it was reported that PHDs are inhibited by
reducing the expression of specific iron chaperones (PCBP1/
PCBP2) that are responsible for delivering Fe(II) to their active
sites (Nandal et al., 2011) (Figure 4). Although these examples
may simply be consistent with the requirement of 2OG oxygen-
ase activity for Fe(II), they also highlight the potential for changes
in Fe(II) availability to modulate hydroxylase activity. Consistent
with this possibility, a prolyl hydroxylase in Pseudomonas has
a relatively high Km for Fe(II) and is implicated in Fe(II) metabolism
(Scotti et al., 2014).
Ascorbate
As discussed in the Introduction, the concept that loss of 2OG
oxygenase activity due to nutrient deprivation could cause
disease was illustrated by scurvy, where reduced collagen
hydroxylase activity results from ascorbate deficiency. Indeed,
other 2OG oxygenases may also be sensitive to ascorbate
levels: supplementing tissue culture media with physiological
levels of ascorbate results in HIFa downregulation due to
increased PHD activity (Knowles et al., 2003). Ascorbate avail-
ability has also been linked to the activity of other 2OG oxy-
genases, particularly TET and KDMs. For example, ascorbate
promotes reprogramming of induced pluripotent stem cells by
inducing the activity of the KDM2 family (Wang et al., 2011). Simi-
larly, ascorbate promotes TET activity and 5-hmC levels to regu-
late stem cell differentiation (Blaschke et al., 2013; Chen et al.,
2013). Not all 2OG oxygenases require ascorbate for activity,
however, raising the possibility that other reducing agents may
also play a role in some circumstances.
2-Oxoglutarate
The possibility that a 2OG oxygenase could act as sensor
of Kreb’s cycle function via 2OG is intriguing. It has been pro-
posed that the HIF PHDs may indirectly sense amino acid avail-
ability via associated changes in 2OG levels (Durán et al., 2013).
Furthermore, increasing intracellular 2OG in hypoxia may be suf-
ficient to activate HIF PHDs in some contexts (Tennant et al.,
2009). Importantly, self-renewal of embryonic stem cells can
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involving activation of H3K27me3 demethylases and TET en-
zymes (Carey et al., 2015). Competitive inhibition of 2OG-binding
by specific tumor-associated metabolites is discussed below.
Oncometabolites Target 2OG Oxygenases in Cancer
The dependence of 2OG oxygenase activity on a fundamental
Kreb’s cycle intermediate may present itself as an ‘‘Achilles’
heel’’ in cancer. Mutation of key metabolic enzymes generates
high levels of intermediates (‘‘oncometabolites’’) that, due to
their structural similarity to 2OG, competitively inhibit a variety
of 2OG oxygenases (Figure 4).
Isocitrate Dehydrogenase
Specific mutations in the catalytic pocket of isocitrate dehydro-
genase 1 (IDH1) and IDH2 are neomorphic in that they switch ac-
tivity from reversible conversion of isocitrate to 2OG, to oxidation
of 2OG to D-2-hydroxyglutarate (D-2HG) (Morin et al., 2014;
Yang et al., 2013b). Thesemutations have been identified in a va-
riety of cancers, including gliomas and acute myeloid leukemia,
where accumulating levels of D-2HG is thought to be a funda-
mental driver of tumorigenesis (Morin et al., 2014). Consistent
with TET enzymes being targets of D-2HG (Figueroa et al.,
2010; Koivunen et al., 2012; Xu et al., 2011), IDH and TET2 mu-
tations are mutually exclusive (Figueroa et al., 2010; Gaidzik
et al., 2012), and DNA from IDH mutant tumors is frequently hy-
permethylated (Ko et al., 2010; Turcan et al., 2012). In fact, de-
regulated epigenetic homeostasis by D-2HG extends beyond
DNA methylation. Histone methylation marks are also elevated
in IDH mutant cells, consistent with competitive inhibition of
KDMs by D-2HG (Chowdhury et al., 2011; Xu et al., 2011). The
effects of IDHmutation on the activity of HIF PHDs appears com-
plex. Although an initial report suggested that IDH mutation was
associated with HIF stabilization (Zhao et al., 2009), subsequent
studies reported that D-2HG can promote PHD in vitro and
reduce hypoxic HIFa induction in vivo (discussed in Losman
and Kaelin, 2013). The ability of D-2HG to stimulate the in vitro
activity of PHDs results from its non-enzymatic conversion into
2OG (Tarhonskaya et al., 2014). Whether this mechanism con-
tributes to the effects of IDH mutation and D-2HG on HIFa regu-
lation in vivo remains unclear.
Fumarate Hydratase and Succinate Dehydrogenase
Loss-of-function mutations in fumarate hydratase (FH), an
enzyme that catalyzes conversion of fumarate to malate, are
associated with elevated fumarate levels and hereditary leio-
myomatosis and renal cell cancer (Yang et al., 2013b). Similarly,
hereditary paraganglioma and pheochromocytoma is associ-
atedwith inactivatingmutations in the four succinate dehydroge-
nase (SDH) subunits (A–D), which prevents the conversion of
succinate into fumarate, leading to massive succinate accumu-
lation (Morin et al., 2014). Exactly how fumarate and succinate
drive tumorigenesis is an area of active investigation. Several
molecular mechanisms have been proposed, which may not
necessarily be mutually exclusive (Morin et al., 2014; Zheng
et al., 2015). One such potential mechanism is the inhibition of
2OG oxygenases via competition with 2OG. Indeed, abnormal
levels of fumarate and succinate inhibit PHDs, causing HIF acti-
vation in normoxia (Morin et al., 2014). This ‘‘pseudo-hypoxia’’
may be a tumor ‘‘driver’’ in some circumstances. For example,inhibition of HIFa expression in tumor cells with stable SDHB
knockdown reduces their growth as xenografts (Guzy et al.,
2008). In contrast, HIFa inhibition does not prevent the formation
of hyperplastic cysts in renal tubules following FH deletion
(Adam et al., 2011). Other mechanisms may therefore contribute
to tumorigenesis driven by FH (and SDH) mutation, including
perhaps the inhibition of other 2OG oxygenases. Interestingly,
histone and DNA methylation are elevated in cells with SDH
loss-of-function, consistent with inhibition of KDM and TET en-
zymes (Morin et al., 2014; Yang et al., 2013b). Treating cells
with fumarate or succinate induces histone methylation marks,
which is phenocopied by knockdown of FH and SDH (Xiao
et al., 2012). Importantly, basal- and TET-induced 5-hmC pro-
duction is also inhibited under these conditions.
Concluding Remarks
Herewe have described 2OGoxygenases as novel enzymes that
catalyze hydroxylation and demethylation of DNA, RNA, and
protein to regulate multiple steps in gene expression. We have
highlighted their potential as nutrient-responsive signaling en-
zymes and discussed the expanding role of 2OG oxygenases
in cancer. Despite these recent insights into the function of
2OG oxygenases, this enzyme family still remains relatively
poorly characterized. Several enzymes remain completely un-
studied and others have only been partially characterized
(Figure 1). It is tempting to speculate that these enzymes may
in the future also be implicated in the emerging themes reviewed
here. It remains a distinct possibility that they might catalyze
unique oxidative modifications to control additional steps in
gene expression.
We have also reviewed the existing evidence supporting the
2OG oxygenase family as a potentially new class of nutrient
sensor. Well-characterized nutrient-responsive signaling mod-
ules include those centered around the AMPK and mTOR
kinases, which signal reductions in the ATP:AMP ratio and amino
acid availability, respectively, to regulate metabolism, nutrient
uptake, and autophagy (Yuan et al., 2013). Crosstalk between
such pathways allows signal integration and fine-tuning of multi-
ple complex biological responses. Therefore, one might predict
the existence of additional layers of crosstalk between these
pathways and members of the 2OG oxygenase family.
As discussed, the reliance of these enzymes on 2OG makes
them vulnerable to competitive inhibition in the context of
oncometabolite-driven cancers. Although initial studies have
characterized the PHD, KDM, and TET families as targets of
oncometabolites, it is possible that inhibition of other 2OG oxy-
genases may also play a role in the pathogenesis of the associ-
ated cancers. For example, it will be interesting to explore
whether the activity of RNA oxygenases and translational
hydroxylases is regulated by oncometabolites. Inhibition of
these 2OG oxygenases by D-2HG, fumarate, or succinate could
contribute to deregulated gene expression control in the context
of IDH, FH, or SDH cancer mutations (Figure 4). As summarized
above, characterized 2OG oxygenases have also been associ-
ated with cancer due to their involvement in hypoxia signaling
and epigenetic regulation and their altered expression, amplifi-
cation, and mutation. Indeed, cancer genetics databases indi-
cate that the importance of these enzymes in cancer is probablyMolecular Cell 58, June 4, 2015 ª2015 Elsevier Inc. 737
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Reviewunderestimated. Considering the significant potential of 2OG
oxygenases as a novel class of drug targets (Rose et al., 2011),
future work investigating the role of these enzymes in gene
expression control and cancer is warranted.ACKNOWLEDGMENTS
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Reviewvan den Born, E., Vågbø, C.B., Songe-Møller, L., Leihne, V., Lien, G.F., Leszc-
zynska, G., Malkiewicz, A., Krokan, H.E., Kirpekar, F., Klungland, A., and
Falnes, P.Ø. (2011). ALKBH8-mediated formation of a novel diastereomeric
pair of wobble nucleosides in mammalian tRNA. Nat. Commun. 2, 172.
Van der Meulen, J., Speleman, F., and Van Vlierberghe, P. (2014).
The H3K27me3 demethylase UTX in normal development and disease. Epige-
netics 9, 658–668.
Wang, T., Chen, K., Zeng, X., Yang, J., Wu, Y., Shi, X., Qin, B., Zeng, L., Este-
ban, M.A., Pan, G., and Pei, D. (2011). The histone demethylases Jhdm1a/1b
enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell
Stem Cell 9, 575–587.
Wang, H., Zhou, X., Wu, M., Wang, C., Zhang, X., Tao, Y., Chen, N., and Zang,
J. (2013). Structure of the JmjC-domain-containing protein JMJD5. Acta Crys-
tallogr. D Biol. Crystallogr. 69, 1911–1920.
Webby, C.J., Wolf, A., Gromak, N., Dreger, M., Kramer, H., Kessler, B., Niel-
sen, M.L., Schmitz, C., Butler, D.S., Yates, J.R., 3rd., et al. (2009). Jmjd6 catal-
yses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing.
Science 325, 90–93.
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